stiinte med 3 2011.indd - Academia de Ştiinţe a Moldovei

Ştiinţe Medicale
in cardiovascular diseases. Clin Chem Lab Med 2004;
42:1085–91.
7. Lee DH, Steffen LM, Jacobs DR. Association
between serum gamma-glutamyltransferase and dietary
factors: CARDIA study. Am J Clin Nutr 2004; 79(4):
600-5.
8. Whitfield JB. Gamma-Glutamyl transferase. Crit
Rev Clin Lab Sci 2001; 38:263–355.
9. Karlson BW, Wiklund O, Hallgren P, Sjolin M,
Lindqvist J, Herlitz J. Ten-year mortality amongst patients
with a very small or unconfirmed acute myocardial
infarction in relation to clinical history, metabolic screening
and signs of myocardial ischemia. J Intern Med, 2000; 247:
449–456.
10. Rantala AO, Lilja M, Kauma H, Savolainen
MJ, Reunanen A, Kesaniemi YA. Gamma-glutamyl
transpeptidase and the metabolic syndrome. J Intern Med,
2000; 248: 230–238, 2000.
11. Nilssen O, Forde OH, Brenn T. The Tromso
Study. Distribution and population determinants of gammaglutamyltransferase.
Am J Epidemiol. 1990;132:318
–326.
12. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp
K, Ulmer H. Gammaglutamyltransferase as a risk factor
for cardiovascular disease mortality: an epidemiological
investigation in a cohort of 163 944 Austrian adults.
Circulation. 2005;112:2130 –2137.
13. Marchesini G, Brizi M, Bianchi G, Tomassetti S,
Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani
G, Melchionda N: Nonalcoholic fatty liver disease: a
feature of the metabolic syndrome. Diabetes, 2001; 50:
1844 –1850.
14. Marchesini G, Forlani G: NASH: from liver
diseases to metabolic disorders and back to clinical
hepatology. Hepatology, 2002; 35:497– 499.
15. Malnick SD, Beergabel M, Knobler H: Nonalcoholic
fatty liver: a common manifestation of a metabolic
disorder. QJM, 2003; 96: 699 –709.
16. Ortega E, Koska J, Salbe AD, Tataranni PA,
Bunt JC. Related Articles, Links Serum gamma-glutamyl
transpeptidase is a determinant of insulin resistance
independently of adiposity in Pima Indian children. J Clin
Endocrinol Metab. 2006; 91:1419 –1422.
17. Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults: Executive
Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III). JAMA, 2001; 285:
2486 –2497.
18. Karp DR, Shimooku K, Lipsky PE. Expression
of gamma-glutamyl transpeptidase protects Ramos B cells
from oxidation-induced cell death. J Biol Chem 2001; 276:
3798–804.
19. Paolicchi A, Emdin M, Ghliozeni E, Ciancia E,
Passino C, Popoff G, Pompella A. Human atherosclerotic
plaques contain gamma-glutamyl transpeptidase enzyme
activity. Circulation. 2004;109:1440.
20. Paolicchi A, Minotti G, Tonarelli P et al.
Gammaglutamyltranspeptidase-dependent iron
347
reduction and LDL oxidation: a potential mechanism in
atherosclerosis. J Invest Med 1999; 47: 151–60.
21. Dominici S, Valentini M, Maellaro E et al. Redox
modulation of cell surface protein thiols in U937 lymphoma
cells: the role of gamma-glutamyl transpeptidase-dependent
H2O2 production and S-thiolation. Free Radic Biol Med,
1999; 27:623–35.
22. Ross R. Mechanism of disease: Atherosclerosis
— an inflammatory disease. N Engl J Med 1999; 340:115–
26.
23. Mitchinson MJ. Toxicity of oxidized LDL towards
mouse peritoneal macrophages in vitro. Atherosclerosis
1993; 98:17–24.
24. Rajagopalan S, Meng XP, Ramasamy S, Harrison
DG, Galis ZS. Reactive oxygen species produced by
macrophage-derived foam cells regulate the activity of
vascular matrix metalloproteinases in vitro. J Clin Invest
1996; 98:2572–9.
25. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum
A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J,
Lisheng L, for the INTERHEART Study Investigators.
Effect of potentially modifiable risk factors associated with
myocardial infarction in 52 countries (the INTERHEART
study): casecontrol study. Lancet. 2004; 364:937–952.
26. Mason JE, Starke RD, Van Kirk JE. Gamma-
Glutamyl Transferase: A Novel Cardiovascular Risk
BioMarker. Prev Cardiol. 2010;13:36–41.
Abstract
Gamma-glutamyltransferase is an established liver
function test and a sensitive marker of hepatic inflammation.
Recent studies have focused increasing attention on the
usefulness of GGT as a predictor of cardiovascular disease.
As a result, identifying higher than expected GGT levels
should alert the physician to study patients more detailed,
with the hopeful outcome of preventing unnecessary
cardiac-related events and deaths in future years.
Rezumat
Gamma-glutamiltransferaza (GGT) se consideră ca
un test funcţional hepatic şi marker sensibil al inflamaţiei
hepatice. Studiile recente au atenţionat privind utilitatea
GGT ca fiind factor predicator al patologiei cardiovasculare.
Determinarea nivelului ridicat al GGT impune studierea
detailată a pacientului cu scopul prevenirii evenimentelor
cardiovasculare şi mortalităţii în anii succesivi.
Резюме
Гамма-глутамилтрансфераза (ГГТ) является признанным
печёночным тестом и чувствительным
маркером печеночного воспаления. В последних исследованиях
все большее внимание было сосредоточено
на использовании ГГТ как предиктора сердечнососудистых
заболеваний. Таким образом, определение
повышенного уровня ГГТ должно побудить врача для
детального исследования пациента с целью предотвращения
развития сердечно-сосудистых осложнений и
смерти в последующие годы.